13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections
Key Takeaways
While asthma is more common in boys during childhood, post-pubertal and adult females exhibit substantially higher asthma prevalence, hospitalization rates, and severity, frequently driven by hormonal fluctuations (perimenstrual or catamenial asthma).
The GINA reports establish Track 1—low-dose Inhaled Corticosteroid (ICS) combined with formoterol as Single Maintenance and Reliever Therapy (SMART/MART)—as the preferred therapeutic paradigm across Steps 1 through 5, eliminating reliance on short-acting beta-2 agonist (SABA) monotherapy.
Asthma in pregnancy adheres to the "Rule of Thirds" (one-third improve, one-third worsen, one-third remain stable), with peak vulnerability to exacerbation occurring between weeks 24 and 36 of gestation.
Uncontrolled maternal asthma presents a far greater risk of fetal hypoxemia, intrauterine growth restriction, preeclampsia, and preterm delivery than any standard asthma medication; inhaled corticosteroids (budesonide preferred, or continuing effective prior ICS) and albuterol rescue are safe throughout pregnancy and lactation.
In primary care respiratory infections, acute bronchitis is overwhelmingly viral (>90%) and antibiotics should be strictly withheld in favor of symptomatic care, while Community-Acquired Pneumonia (CAP) is stratified by CURB-65 criteria and treated empirically with amoxicillin or doxycycline (or beta-lactam plus macrolide in pregnancy, avoiding fluoroquinolones and tetracyclines).
Sex Differences in Asthma Epidemiology & Perimenstrual Asthma
Asthma is a chronic inflammatory airway disorder characterized by bronchial hyperresponsiveness, mucosal edema, and variable airflow obstruction. A notable epidemiologic shift occurs across the lifespan: in children under age 12, asthma prevalence and hospitalizations are twice as high in boys compared to girls, reflecting smaller airway caliber relative to lung volume. Following puberty, this sex ratio reverses. Adult women exhibit significantly higher asthma prevalence, more frequent severe exacerbations, increased emergency department visits, and more than double the hospitalization rates of men.
Female sex hormones profoundly modulate airway biology:
- Estrogen & Progesterone Influences: 17-beta-estradiol promotes Th2 eosinophilic airway inflammation and upregulates nitric oxide synthase, while progesterone influences airway smooth muscle tone and beta-2 adrenergic receptor density.
- Perimenstrual Asthma (PMA / Catamenial Asthma): Between 30% and 40% of asthmatic women experience cyclical worsening of symptoms and peak expiratory flow (PEF) in the premenstrual and early menstrual window (days -4 to +2 of menses). PMA is triggered by the rapid drop in circulating estradiol and progesterone, producing a surge in pro-inflammatory cysteinyl leukotrienes and heightened bronchial hyperreactivity. Management strategies include adding a leukotriene receptor antagonist (LTRA; montelukast 10 mg PO daily), premenstrual step-up of inhaled corticosteroids, or hormonal suppression of cyclical drops with continuous combined oral contraceptives.
Stepwise Asthma Pharmacotherapy: The GINA & NHLBI Guidelines
The Global Initiative for Asthma (GINA) no longer recommends short-acting beta-2 agonist (SABA) monotherapy (as-needed albuterol alone), and the 2020 NHLBI focused update endorses ICS-formoterol single maintenance and reliever therapy (SMART) for moderate persistent asthma (steps 3–4). SABA monotherapy relieves bronchospasm without treating underlying inflammation, leading to beta-receptor downregulation, tolerance, rebound hyperresponsiveness, and increased exacerbation risk.
GINA designates Track 1 (ICS-Formoterol as Single Maintenance and Reliever Therapy, SMART/MART) as the preferred strategy across all severity steps:
| Step | GINA Track 1 (Preferred: SMART / MART) | GINA Track 2 (Alternative Strategy) |
|---|---|---|
| Step 1 & 2 | As-needed low-dose ICS-formoterol (e.g., budesonide-formoterol 80/4.5 or 160/4.5 mcg, 1 puff PRN for relief) | Daily low-dose ICS maintenance PLUS as-needed SABA (or take low-dose ICS whenever SABA is inhaled) |
| Step 3 | Low-dose ICS-formoterol maintenance (1 puff daily or BID) PLUS as-needed low-dose ICS-formoterol reliever | Daily low-dose ICS-LABA maintenance PLUS as-needed SABA |
| Step 4 | Medium-dose ICS-formoterol maintenance (2 puffs BID) PLUS as-needed low-dose ICS-formoterol reliever | Daily medium-to-high dose ICS-LABA maintenance PLUS as-needed SABA |
| Step 5 | High-dose ICS-formoterol maintenance + add-on LAMA (tiotropium); phenotyping for biologic therapy | Daily high-dose ICS-LABA + add-on LAMA; phenotyping for biologic therapy |
Formoterol is uniquely suited for SMART because it provides rapid bronchodilation (onset 1–3 minutes, comparable to albuterol) alongside a 12-hour duration of action. Taking ICS-formoterol for symptom relief delivers anti-inflammatory corticosteroid at the earliest sign of airway worsening. In Step 5, phenotypic evaluation directs add-on biologics: anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, benralizumab), anti-IL-4R-alpha (dupilumab), and anti-TSLP (tezepelumab).
Asthma Management in Pregnancy & Lactation
Asthma affects 8% to 10% of pregnant women. Its clinical course classically follows the "Rule of Thirds":
- One-third of women experience symptom improvement (mediated by increased free cortisol and progesterone).
- One-third remain unchanged.
- One-third experience symptom worsening, with peak vulnerability occurring between weeks 24 and 36 of gestation (exacerbations during active labor are rare, <10%).
Important
Clinical Principle: Uncontrolled Asthma vs Medication Safety in Pregnancy: Uncontrolled maternal asthma presents a far greater risk to maternal and fetal well-being than any standard asthma medication. Maternal hypoxemia impairs uteroplacental perfusion, causing fetal hypoxia, intrauterine growth restriction (IUGR), oligohydramnios, preeclampsia, preterm delivery, and low birth weight.
- Inhaled Corticosteroids (ICS): The foundation of persistent asthma care. Budesonide has the most extensive human pregnancy safety data; however, if a patient is well-controlled on another ICS (e.g., fluticasone, mometasone) prior to pregnancy, she should continue her established medication to avoid loss of disease control.
- Rescue Bronchodilator: Inhaled albuterol is the preferred first-line SABA in pregnancy.
- Systemic Steroids: For moderate-to-severe exacerbations, oral prednisone (40–60 mg/day for 5 days) or IV methylprednisolone must not be withheld; maternal stabilization is essential to prevent fetal asphyxia.
- Lactation: Budesonide, fluticasone, and albuterol transfer into breast milk in negligible amounts and are safe during breastfeeding.
Acute Exacerbation Triage & Fetal Oxygenation Targets
Progesterone stimulates the medullary respiratory center, increasing minute ventilation by 30% to 50% and producing a physiologic chronic respiratory alkalosis (normal pregnancy PaCO2: 28–32 mmHg; pH: 7.40–7.45; HCO3: 18–22 mEq/L). Consequently, a "normal" PaCO2 of 35 to 40 mmHg during an asthma exacerbation indicates respiratory muscle exhaustion and impending respiratory arrest.
Maternal pulse oximetry must be maintained at SpO2 ≥95% (or PaO2 >70 mmHg) at all times to guarantee adequate transplacental oxygen delivery to the fetus. Treatment includes high-flow oxygen, repetitive nebulized albuterol (2.5 mg) plus ipratropium bromide (0.5 mg), systemic corticosteroids, continuous fetal monitoring if viable (≥24 weeks), and serial peak flow measurements.
Upper & Lower Respiratory Infections in Primary Care
Acute Bronchitis
Acute bronchitis is a self-limiting inflammation of the large airways presenting with cough (with or without sputum), wheezing, and chest discomfort lasting 10 to 21 days (median 18 days).
- Etiology: Over 90% of cases are viral (influenza, parainfluenza, RSV, coronavirus, rhinovirus). Bacterial pathogens (Bordetella pertussis, Mycoplasma pneumoniae) account for <10%.
- Antimicrobial Stewardship: Antibiotics are strictly not indicated, as randomized trials demonstrate no reduction in cough duration alongside significant adverse effects and resistance risks.
- Symptomatic Relief: Patient education regarding the typical 2- to 3-week course, hydration, guaifenesin (expectorant), dextromethorphan (antitussive), and honey (patients >1 year). Inhaled albuterol is reserved strictly for auscultated wheezing.
Community-Acquired Pneumonia (CAP)
Pneumonia presents with fever, chills, productive cough, dyspnea, and focal lung crackles or consolidation confirmed on chest radiography (with abdominal shielding in pregnancy).
- CURB-65 Criteria: Confusion (1 pt), Urea/BUN >20 mg/dL (1 pt), Respiratory rate ≥30/min (1 pt), Blood pressure <90/60 mmHg (1 pt), Age ≥65 (1 pt). Score 0–1: outpatient care; Score 2: consider hospital admission; Score ≥3: inpatient admission.
- Outpatient Antibiotic Regimens:
- Healthy adults: Amoxicillin 1 g PO TID OR Doxycycline 100 mg PO BID (macrolide monotherapy only if local resistance <25%).
- Adults with comorbidities: Amoxicillin-clavulanate (875/125 mg PO BID) PLUS a macrolide (Azithromycin) or Doxycycline; OR respiratory fluoroquinolone monotherapy (Levofloxacin 750 mg daily).
- Gestational Safety Contraindications:
- Fluoroquinolones (levofloxacin, ciprofloxacin): Contraindicated in pregnancy and lactation due to fetal cartilage damage and arthropathy.
- Tetracyclines (doxycycline): Contraindicated in the 2nd and 3rd trimesters due to permanent fetal tooth discoloration and bone growth inhibition.
- Pregnancy First-Line: Amoxicillin-clavulanate (875/125 mg BID) PLUS oral Azithromycin (500 mg day 1, then 250 mg daily).
A 28-year-old primigravida at 28 weeks gestation with a history of moderate persistent asthma presents for routine prenatal care. She reports that 4 weeks ago she stopped her daily inhaled fluticasone and salmeterol inhaler after reading online that steroids harm the developing fetus. Over the past 2 weeks, she has experienced nocturnal cough awakening her twice weekly, daytime dyspnea, and has used her albuterol rescue inhaler 4 to 5 times per week. Her vital signs reveal BP 114/72 mmHg, HR 86 bpm, RR 20 bpm, and room air SpO2 94%. Physical examination demonstrates bilateral expiratory wheezes. What is the most appropriate management plan?
Reassure the patient that stopping medications was appropriate, switch her to oral terbutaline as-needed, and target an SpO2 of 90%.
Restart her ICS-LABA controller, explain that uncontrolled asthma is riskier for the fetus than the drugs, and add albuterol as needed.
Prescribe a 14-day course of oral azithromycin for suspected atypical pneumonia and avoid all inhaled bronchodilators.
Advise strict bed rest and withhold all asthma pharmacotherapy until after delivery to prevent neonatal adrenal suppression.
A 33-year-old female with moderate persistent asthma managed on low-dose budesonide-formoterol maintenance and reliever therapy (SMART). She tracks her peak expiratory flows (PEF) and notes that predictably, 3 to 4 days prior to the onset of menses each month, her PEF drops by 25% to 30%, accompanied by severe chest tightness, nocturnal awakenings, and increased reliever use, which abruptly resolve on day 2 of menstruation. What condition does this represent, and what is an evidence-based adjunctive treatment strategy?
Perimenstrual asthma (PMA); add a leukotriene receptor antagonist (e.g., montelukast 10 mg daily) or continuous hormonal contraception to suppress cyclic endocrine drops.
Premenstrual dysphoric disorder (PMDD); initiate fluoxetine 20 mg daily during the luteal phase and discontinue all asthma inhalers.
Exercise-induced bronchospasm; instruct the patient to avoid all physical activity during the week preceding menstruation.
Aspirin-exacerbated respiratory disease (AERD); instruct the patient to discontinue paracetamol and initiate daily high-dose aspirin desensitization.
A 31-year-old female at 22 weeks gestation presents to the clinic with a 4-day history of productive cough with rust-colored sputum, right-sided pleuritic chest pain, chills, and fever up to 38.8°C (101.8°F). Physical examination reveals a respiratory rate of 20 breaths/min, blood pressure 114/72 mmHg, room air SpO2 96%, and focal crackles with bronchial breath sounds at the right lung base. Chest radiography with abdominal lead shielding demonstrates a right lower lobe alveolar consolidation. CURB-65 score is 0. She has no chronic medical conditions and no known drug allergies. What is the most appropriate outpatient antimicrobial regimen?
Levofloxacin 750 mg once daily for 5 days as monotherapy
Doxycycline 100 mg twice daily for 7 days
Amoxicillin-clavulanate twice daily plus azithromycin
Ciprofloxacin 500 mg twice daily for 10 days
Sections you finish are checked off in the contents.